A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema

NCT02281292 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Management Decision

Conditions

Diabetic Macular Edema

Interventions

BIOLOGICAL: LKA651 ophthalmic solution
BIOLOGICAL: Ranibizumab ophthalmic solution
BIOLOGICAL: Sham injection

Sponsor

Alcon Research

Collaborators

[object Object]